Here's why the Patrys (ASX: PAB) share price is climbing 13% today

This small-cap ASX share revealed some exciting news today.

| More on:
A medical researcher in a white coat holds laboratory equipment and smiles.

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Patrys Limited (ASX: PAB) share price is starting the week on a strong note. This comes after the therapeutic antibody development company announced new data from non-clinical studies of its cancer-fighting antibody, PAT-DX3.

Patrys is developing a full-sized immunoglobulin G (IgG) antibody and humanised version of a smaller deoxymab antibody fragment to treat cancers through DNA.

During morning trade, the company's shares are up 13.73% to 5.8 cents.

What did Patrys announce?

In a statement to the ASX, Patrys advised that PAT-DX3 is able to cross the blood-brain barrier (BBB) in an animal model of primary brain cancer. This includes the most aggressive type of cancer, glioblastoma multiforme (GBM).

The company noted that previous studies showed a smaller antibody fragment, PAT-DX1, can cross the BBB. However, this is the first time a full-sized deoxymab (PAT-DX3) has done so.

The company is now planning follow-up studies to compare the effects of both PAT-DX1 and PAT-DX3. Patrys will look at tumour reduction and survival in a range of primary and secondary brain cancer models.

In addition, PAT-DX3 is also being tested to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumours. This allows specific delivery of cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells.

Patrys CEO and managing director Dr James Campbell said:

We are very excited by this new discovery that opens up a range of development and partnering opportunities for Patrys around PAT-DX3.

As PAT-DX3 shares a common mechanism of action with PAT-DX1, it is expected that it will also localise to both primary and secondary tumours in the brain and selectively kill cancer cells by blocking their DNA Damage Repair (DDR) systems. While Patrys remains focused on preparing for its first-in-human study of PAT-DX1, it is clear that PAT-DX3 is a valuable addition to the company's deoxymab antibody platform.

About the Patrys share price

During the last 12 months, the Patrys share price has accelerated by more than 380% and more than 141% in 2021. It's worth noting the company's share price is nearing its 52-week high of 6.3 cents achieved late last month.

Patrys has a market capitalisation of roughly $105 million, with approximately 1.8 billion shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Woman in celebratory fist move looking at phone
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A female financial services professional with a manicured black afro hairstyle turns an ipad screen to show a client across the table a set of ASX shares figures in graph format.
Share Market News

Record CBA share price and blockbuster merger push ASX 200 financials sector to the top

ASX financial stocks led the 11 market sectors last week with a 1.95% gain.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Market News

CBA Shares in focus: How Australia's most valuable company is using AI to compete

Could AI initiatives drive CBA shares higher?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Looking for big returns? Brokers think these shares could do the job.

Read more »

asx share price represented by cartoon letters spelling the word FOMO
Share Market News

What did Macquarie's "FOMO Meter" reveal about the stock market in May?

Is the market getting frothy or is there still room to climb?

Read more »

Market up or down
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the week...

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Share Gainers

4 ASX 200 shares racing ahead of the benchmark this week

ASX investors sent these four stocks soaring 12% to 18% this week. But why?

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »